Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | MC5R | P33032 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1306165 | 0.93 | CYP1A2 (0.48) | CYP1A2CYP2A6SIGMAR1HRH3SLC6A4 | |
| SCHEMBL128560 | 0.87 | SIGMAR1 (0.59) | CYP1A2CYP2A6SIGMAR1HRH3SLC6A4 | |
| SCHEMBL6240981 | 0.85 | CYP1A2 (0.65) | CYP1A2CYP2A6SIGMAR1HRH3SLC6A4 | |
| SCHEMBL29560700 | 0.85 | CYP1A2 (0.65) | CYP1A2CYP2A6SIGMAR1HRH3SLC6A4 | |
| SCHEMBL133399 | 0.85 | SIGMAR1 (0.58) | CYP1A2CYP2A6SIGMAR1HRH3SLC6A4 | |
| SCHEMBL1610345 | 0.84 | SIGMAR1 (0.56) | CYP1A2CYP2A6SIGMAR1HRH3SLC6A4 | |
| SCHEMBL129049 | 0.84 | SIGMAR1 (0.56) | CYP1A2CYP2A6SIGMAR1HRH3SLC6A4 | |
| SCHEMBL1610472 | 0.84 | SIGMAR1 (0.56) | CYP1A2CYP2A6SIGMAR1HRH3SLC6A4 | |
| SCHEMBL27523237 | 0.82 | SIGMAR1 (0.54) | CYP1A2CYP2A6SIGMAR1HRH3SLC6A4 | |
| SCHEMBL26213 | 0.81 | CYP1A2 (0.60) | CYP1A2CYP2A6SIGMAR1HRH3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1406 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023023513-A9 | STABILIZATION OF OLIGONUCLEOTIDE AND OLIGONUCLEOTIDE-PROTEIN COMPLEX USING ALKYLATED PHOSPHATE | UNIVERSITY OF MASSACHUSETTS (US) | 2023-06-01 | — | — | WO | claimed |
| WO-2023023513-A1 | STABILIZATION OF OLIGONUCLEOTIDE AND OLIGONUCLEOTIDE-PROTEIN COMPLEX USING ALKYLATED PHOSPHATE | UNIVERSITY OF MASSACHUSETTS (US) | 2023-02-23 | — | — | WO | claimed |
| US-11059818-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-13 | — | — | US | claimed |
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | claimed |
| US-20200291015-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | claimed |
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | claimed |
| US-20190218219-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-07-18 | — | — | US | claimed |
| WO-2017160632-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-21 | — | — | WO | claimed |
| WO-2017161145-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-21 | — | — | WO | claimed |
| CN-1738829-B | New 2',5'-oligoadenylic acid analog | SANKYO CO | 2012-11-28 | — | — | CN | claimed |
| WO-2000009479-A2 | HETEROCYCLIC THIOESTERS OR KETONES FOR VISION AND MEMORY DISORDERS | GPI NIL HOLDINGS, INC. (US) | 2000-02-24 | — | — | WO | claimed |
| EP-0966456-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-12-29 | — | — | EP | claimed |
| WO-1999062488-A1 | HETEROCYCLIC THIOESTER AND KETONE HAIR GROWTH COMPOSITIONS AND USES | GPI NIL HOLDINGS, INC. (US) | 1999-12-09 | — | — | WO | claimed |
| US-5990131-A | OF GIVEN FORMULA WHICH HAVE A HIGH AFFINITY FOR FKBPS (FK506 BINDING PROTEINS, A CLASS OF IMMUNOPHILINS) ARE POTENT ROTAMASE INHIBITORS AND EXHIBIT EXCELLENT NEUROTROPHIC EFFECTS; NO IMMUNOSUPPRESSIVE ACTIVITY | GPI NIL HOLDINGS INC. (US) | 1999-11-23 | — | — | US | claimed |
| EP-0934263-A1 | HETEROCYCLIC THIOESTERS AND KETONES | GUILFORD PHARMACEUTICALS INC. (US) | 1999-08-11 | — | — | EP | claimed |
| US-5811452-A | ADMINISTERING WITH PACLITAXEL OR DOXORUBICIN | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-09-22 | — | — | US | claimed |
| WO-1998030553-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-07-16 | — | — | WO | claimed |
| WO-1998013343-A1 | HETEROCYCLIC THIOESTERS AND KETONES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| EP-0807114-A1 | BRIDGED INDOLES AS MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-11-19 | — | — | EP | claimed |
| WO-1996023791-A1 | BRIDGED INDOLES AS MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-08-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218219-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | CYCS, HCCS, IDH3B | CYP1A2 110/4885CYP2A6 2086/4885SIGMAR1 1621/4885 |
| US-20200291015-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | MPO, NOX5, SERPINB1 | CYP1A2 180/4885CYP2A6 1322/4885SIGMAR1 2852/4885 |
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | EPX, MPO, SERPINB1 | CYP1A2 328/4885CYP2A6 1765/4885SIGMAR1 3710/4885 |
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | EPX, MPO, SERPINB1 | CYP1A2 328/4885CYP2A6 1765/4885SIGMAR1 3710/4885 |
| US-11059818-B2 | Triazolopyridine inhibitors of myeloperoxidase | MPO, NOX5, SERPINB1 | CYP1A2 180/4885CYP2A6 1322/4885SIGMAR1 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.